Lyophilization above collapse
View Patent ↗The present invention provides methods of lyophilizing a pharmaceutical substance involving a primary drying step executed at a product temperature at or above the collapse temperature. The invention also provides pharmaceutical substances lyophilized at or above the collapse temperature.
1. A method of lyophilizing a pharmaceutical substance in an aqueous liquid formulation, comprising:
(a) a freezing step, wherein water in the liquid formulation is converted to ice,
(b) followed by a primary drying step conducted in a lyophilizer, characterized in that the primary drying step consists of removing water in the pharmaceutical substance by direct sublimation, and is executed at a product temperature at or above the macro-collapse temperature without avoiding cake macro-collapse, and at a pressure below about 500 mTorr,
wherein macro-collapse temperature is the temperature at which the lyophilized cake has visually detectable collapse, and is at least 5° C. above the mid-point of glass transition temperature (Tg′);
wherein the lyophilized pharmaceutical substance is suitable for later reconstitution to a biologically or pharmaceutically active substance; and
wherein said pharmaceutical substance is at a concentration of at least 10 mg/ml in said aqueous liquid formulation.
2. The method of claim 1 , wherein the pharmaceutical substance is selected from the group consisting of a protein, a peptide, a polysaccharide, a small molecule, a natural product, a nucleic acid, an immunogen, a vaccine, a polymer, a chemical compound, and a combination thereof.
3. The method of claim 1 , wherein the primary drying step is performed at a product temperature that is below the onset temperature of the melting endotherm of the frozen formulation of step (a).
4. The method of claim 3 , further comprising determining the onset temperature of the melting endotherm of the frozen formulation by Differential Scanning calorimetry (DSC).
5. The method of claim 1 , wherein the pharmaceutical substance is at a concentration of at least 50 mg/ml in the liquid formulation.
6. The method of claim 1 , wherein the pharmaceutical substance is at a concentration of at least 100 mg/ml in the liquid formulation.
7. The method of claim 1 , wherein the lyophilized product comprises amorphous materials.
8. The method of claim 1 , wherein the lyophilized product comprises partly crystalline/partly amorphous materials.
9. The method of claim 1 , wherein the liquid formulation is a sucrose-based formulation.
10. The method of claim 1 , wherein the freezing step produces a solid product with a product temperature of about −20° C. to about −70° C.
11. The method of claim 1 , wherein the freezing step produces a solid product with a product temperature of about −40° C. to about −70° C.
12. The method of claim 1 , wherein the primary drying step is performed at a pressure below about 200 mTorr.
13. The method of claim 1 , wherein said liquid formulation comprises histidine, sucrose, and mannitol.
14. The method of claim 1 , wherein the pharmaceutical substance is at a concentration of at least 20 mg/ml in the liquid formulation.
15. The method of claim 1 , wherein said lyophilizer is a commercial-scale lyophilizer.
16. A method of lyophilizing a pharmaceutical substance in an aqueous liquid formulation, comprising:
(a) a freezing step, wherein water in the liquid formulation is converted to ice,
(b) followed by a primary drying step conducted in a lyophilizer, characterized in that the primary drying step consisting of removing water in the pharmaceutical substance by direct sublimation, and is executed at a product temperature at or above the macro-collapse temperature without avoiding cake macro-collapse, and at a pressure below about 500 mTorr,
wherein macro-collapse temperature is the temperature at which the lyophilized cake has visually detectable collapse, and is at least 3° C. above the mid-point of glass transition temperature (Tg′);
wherein the lyophilized pharmaceutical substance is suitable for later reconstitution to a biologically or pharmaceutically active substance,
wherein the liquid formulation comprises a stabilizing agent,
wherein said pharmaceutical substance is at a concentration of at least 10 mg/ml in said aqueous liquid formulation, and
wherein the ratio of the mass amount of the stabilizing agent and said pharmaceutical substance is no greater than 1000.
17. The method of claim 16 , wherein the pharmaceutical substance is at a concentration of at least about 20 mg/ml in the liquid formulation.
18. The method of claim 16 , wherein the pharmaceutical substance is at a concentration of at least 50 mg/ml in the liquid formulation.
19. The method of claim 16 , wherein the stabilizing agent is selected from the group consisting of sucrose, mannose, sorbitol, raffinose, trehalose, mannitol, sodium chloride, arginine, lactose, hydroxyethyl starch, dextran, polyvinylpyrolidone, glycine, and a combination thereof.
20. The method of claim 16 , wherein the lyophilized product comprises amorphous materials.
21. The method of claim 16 , wherein the lyophilized product comprises partly crystalline/partly amorphous materials.
22. The method of claim 16 , wherein the pharmaceutical substance is selected from the group consisting of a protein, a peptide, a polysaccharide, a small molecule, a natural product, a nucleic acid, an immunogen, a vaccine, a polymer, a chemical compound, and a combination thereof.
23. The method of claim 22 , wherein the pharmaceutical substance is a protein.
24. The method of claim 23 , wherein the protein is selected from the group consisting of an antibody or a fragment thereof, a growth factor, a clotting factor, a cytokine, a fusion protein, an enzyme, a carrier protein, a polysaccharide-containing antigen, a Small Modular ImmunoPharmaceutical, and a combination thereof.
25. The method of claim 24 , wherein the antibody is a monoclonal antibody or a single-domain antibody.
26. The method of claim 16 , wherein the liquid formulation is formulated such that the macro-collapse temperature is at least 5° C. higher than the middle point of glass transition temperature (Tg′).
27. The method of claim 16 , wherein the pharmaceutical substance is at a concentration of at least 100 mg/ml in the liquid formulation.
28. The method of claim 16 , wherein said lyophilizer is a commercial-scale lyophilizer.
29. A method of lyophilizing a pharmaceutical substance in an aqueous liquid formulation, wherein said pharmaceutical substance is a protein, comprising:
(a) a freezing step, wherein water in the liquid formulation is converted to ice,
(b) followed by a primary drying step conducted in a lyophilizer, characterized in that the primary drying step consists of removing water in the pharmaceutical substance by direct sublimation, and is executed at a product temperature at or above the macro-collapse temperature without avoiding cake macro-collapse, and at a pressure below about 500 mTorr,
wherein macro-collapse temperature is the temperature at which the lyophilized cake has visually detectable collapse, and is at least 3° C. above the mid-point of glass transition temperature (Tg′);
wherein the lyophilized pharmaceutical substance is suitable for later reconstitution to a biologically or pharmaceutically active substance; and
wherein said pharmaceutical substance is at a concentration of at least 10 mg/ml in said aqueous liquid formulation.
30. The method of claim 29 , wherein the protein is selected from the group consisting of an antibody or a fragment thereof, a growth factor, a clotting factor, a cytokine, a fusion protein, an enzyme, a carrier protein, a Small Modular ImmunoPharmaceutical, and a combination thereof.
31. A method of storing a pharmaceutical substance comprising:
(a) lyophilizing the pharmaceutical substance in an aqueous liquid formulation, comprising:
(i) a freezing step, wherein water in the pharmaceutical substance is converted to ice,
(ii) followed by a primary drying step conducted in a lyophilizer, characterized in that the primary drying step consists of removing water in the pharmaceutical substance by direct sublimation, and is executed at a product temperature at or above the macro-collapse temperature without avoiding cake macro-collapse, and at a pressure below about 500 mTorr,
wherein macro-collapse temperature is the temperature at which the lyophilized cake has visually detectable collapse, and is at least 3° C. above the mid-point of glass transition temperature (Tg′);
wherein said pharmaceutical substance is at a concentration of at least 10 mg/ml in said aqueous liquid formulation, and
wherein the lyophilized pharmaceutical substance is suitable for later reconstitution to a biologically or pharmaceutically active substance;
(b) storing the lyophilized pharmaceutical substance for a period longer than 3 months.
32. The method of claim 31 , wherein the liquid formulation is formulated such that the macro-collapse temperature is at least 5° C. higher than the middle point of glass transition temperature (Tg′).
33. The method of claim 31 , wherein the pharmaceutical substance is at a concentration of at least 20 mg/ml in the liquid formulation.
34. The method of claim 31 , wherein the pharmaceutical substance is at a concentration of at least 50 mg/ml in the liquid formulation.
35. The method of claim 31 , wherein the pharmaceutical substance is at a concentration of at least 100 mg/ml in the liquid formulation.
36. The method of claim 31 , wherein said lyophilizer is a commercial-scale lyophilizer.
37. A method of lyophilizing a pharmaceutical substance in an aqueous liquid formulation, comprising:
(a) a freezing step, wherein water in the liquid formulation is converted to ice and produces a solid product with a product temperature of about −40° C. to about −70° C.,
(b) followed by a primary drying step conducted in a lyophilizer, characterized in that the primary drying step removes water in the pharmaceutical substance by direct sublimation, and is executed at a product temperature at or above the macro-collapse temperature without avoiding cake macro-collapse, and at a pressure at or below about 200 mTorr,
wherein macro-collapse temperature is the temperature at which the lyophilized cake has visually detectable collapse, and is at least 3° C. above the mid-point of glass transition temperature (Tg′);
wherein the lyophilized pharmaceutical substance is suitable for later reconstitution to a biologically or pharmaceutically active substance;
wherein the pharmaceutical substance comprises a protein, a peptide, a polysaccharide, a small molecule, a natural product, a nucleic acid, an immunogen, a vaccine, a polymer, a chemical compound, or a combination thereof; and
wherein the pharmaceutical substance is contained in the liquid formulation at a concentration of 50 mg/ml, the liquid formulation further comprising 5% (or 50 mg/ml) sucrose, 10 mM histidine, 10 mM methionine, and 0.01% (or 0.1 mg/ml) polysorbate 80.
38. A method of lyophilizing a pharmaceutical substance in an aqueous liquid formulation, comprising:
(a) a freezing step, wherein water in the liquid formulation is converted to ice and produces a solid product with a product temperature of about −40° C. to about −70° C.,
(b) followed by a primary drying step conducted in a lyophilizer, characterized in that the primary drying step removes water in the pharmaceutical substance by direct sublimation, and is executed at a product temperature at or above the macro-collapse temperature without avoiding cake macro-collapse, and at a pressure at or below about 200 mTorr,
wherein macro-collapse temperature is the temperature at which the lyophilized cake has visually detectable collapse, and is at least 3° C. above the mid-point of glass transition temperature (Tg′);
wherein the lyophilized pharmaceutical substance is suitable for later reconstitution to a biologically or pharmaceutically active substance;
wherein the pharmaceutical substance comprises a protein selected from the group consisting of:
an antibody or a fragment thereof, a growth factor, a clotting factor, a cytokine, a fusion protein, an enzyme, a carrier protein, a Small Modular ImmunoPharmaceutical, and a combination thereof; and
wherein the pharmaceutical substance is contained in the liquid formulation at a concentration of 10 mg/ml, the liquid formulation further comprising 10 mM Tris, 4% (or 40 mg/ml) mannitol, and 1% (or 10 mg/ml) sucrose, at pH 7.4.